Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 303 Brookline Avenue, Boston, MA 02215, USA.
Department of Pathology, Yale School of Medicine, 310 Cedar Street, PO Box 208023, New Haven, CT 06520-8023, USA.
Clin Liver Dis. 2020 Nov;24(4):591-610. doi: 10.1016/j.cld.2020.07.010. Epub 2020 Sep 3.
Hepatocellular carcinoma (HCC) is a morphologically heterogeneous tumor with variable architectural growth patterns and several distinct histologic subtypes. Large-scale attempts have been made over the past decade to identify targetable genomic alterations in HCC; however, its translation into clinical personalized care remains a challenge to precision oncology. The role of pathology is no longer limited to confirmation of diagnosis when radiologic features are atypical. Pathology is now in a position to predict the underlying molecular alteration, prognosis, and behavior of HCC. This review outlines various aspects of histopathologic diagnosis and role of pathology in cutting-edge diagnostics of HCC.
肝细胞癌 (HCC) 是一种形态学上具有异质性的肿瘤，具有不同的结构生长模式和几种不同的组织学亚型。在过去十年中，人们进行了大规模的尝试以确定 HCC 中可靶向的基因组改变；然而，将其转化为临床个性化护理仍然是精准肿瘤学的一个挑战。当影像学特征不典型时，病理学的作用不再局限于确诊。病理学现在能够预测 HCC 的潜在分子改变、预后和行为。这篇综述概述了 HCC 的组织病理学诊断的各个方面以及病理学在 HCC 的前沿诊断中的作用。
